ShallowBench: Benchmarking Generative Drug Design Models on Shallow-Pocket Targets
While generative AI models have demonstrated remarkable success in structure-based drug design, they predominantly rely on deep binding pockets and struggle to sample effective ligands for challenging low-pocketability targets, such as the historically "undruggable" oncology targets KRAS and MYC. To address this gap, we introduce ShallowBench, a strictly curated benchmark of 5,780 shallow-pocket targets extracted from CrossDocked2020. By computing the difference between an Alpha Shape "lid" volume and the underlying protein atom voxel volume, we successfully isolated targets with low concavity while ensuring sufficient surface area for binding. Evaluating various state-of-the-art generative models reveals weaker predicted binding affinity on these low-concavity interfaces. ShallowBench therefore provides a rigorous benchmark for generative biology models and highlights the necessity of new architectural innovations or loss functions capable of navigating these challenging targets.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Benchmarking Deep Graph Generative Models for Optimizing New Drug Molecules for COVID-19
Design of new drug compounds with target properties is a key area of research in generative modeling. We present a small drug molecule design pipeline based on graph-generative models and a comparison study of two state-…
BenchmarkingQ-LearningThe Jungle of Generative Drug Discovery: Traps, Treasures, and Ways Out
"How to evaluate de novo designs proposed by a generative model?" Despite the transformative potential of generative deep learning in drug discovery, this seemingly simple question has no clear answer. The absence of sta…
BenchmarkingDeep LearningDrug DiscoveryNavigateACEGEN: Reinforcement learning of generative chemical agents for drug discovery
In recent years, reinforcement learning (RL) has emerged as a valuable tool in drug design, offering the potential to propose and optimize molecules with desired properties. However, striking a balance between capabiliti…
BenchmarkingDecision MakingDrug DesignDrug Discovery+3A Comprehensive Benchmarking Platform for Deep Generative Models in Molecular Design
The development of novel pharmaceuticals represents a significant challenge in modern science, with substantial costs and time investments. Deep generative models have emerged as promising tools for accelerating drug dis…
BenchmarkingDrug DiscoveryvalidA biologically-inspired multi-modal evaluation of molecular generative machine learning
While generative models have recently become ubiquitous in many scientific areas, less attention has been paid to their evaluation. For molecular generative models, the state-of-the-art examines their output in isolation…
BenchmarkingDrug DiscoveryMolecular Docking